Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Pliant Therapeutics has raised $287.5M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in January 2023.
Pliant Therapeutics's investors include Menlo Ventures, Cormorant Asset Management, Redmile Group, Third Rock Ventures, Farallon Capital Management.
Pliant Therapeutics is headquartered in South San Francisco, United States.
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Pliant Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Pliant Therapeutics — Funding & Investors." VCBacked, January 24, 2023, https://www.vcbacked.co/company/pliant-therapeutics. Accessed November 12, 2026.
VCBacked. (2023). Pliant Therapeutics — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/pliant-therapeutics
{{cite web |title=Pliant Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/pliant-therapeutics |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Pliant Therapeutics? Request a listing update